BASIC RESEARCH

Acute and subchronic toxicological evaluation of Echinophora platyloba DC (Apiaceae) total extract in Wistar rats

Sayid Mahdi Mirghazanfari, Leila Hosseinzadeh, Yalda Shokoohinia, Majid Aslany, Mohammad Kamali-Nejad

OBJECTIVE: Echinophora platyloba DC is a widely used herbal medicine and food seasoning in Iran. It is claimed to exert antimicrobial, antifungal, and antispasmodic effects. Despite the prevalent use of this plant as a food and medicine, there are no reports on its possible toxic effects. To evaluate the safety of E. platyloba, we tested its acute and sub-chronic toxicity in male and female Wistar rats.

METHODS: Rats were orally treated with four different single doses of E. platyloba total extract and screened for signs of toxicity two weeks after administration. In the sub-chronic toxicity study, E. platyloba was administered for 45 days. Mortality, clinical signs, body weight changes, hematological and biochemical parameters, gross findings, organ weights, and histological markers were monitored during the study.

RESULTS: We found no mortality and no abnormality in clinical signs, body weight, or necropsy findings in any of the animals in the acute study. The results of the subchronic study showed no significant difference in hematological parameters in either sex. There was a significant increase in lactate dehydrogenase in the female groups. A significant increase in the relative lung weight of female rats was noted at 500 mg/kg. Histopathological examinations revealed intra-alveolar hemorrhage in the male rats (500 mg/kg). In the females, congestion of the alveolar capillaries (at 500 mg/kg) and liver bridging necrosis (at 200 mg/kg) were significantly increased.

CONCLUSION: The no observed adverse effect level of E. platyloba was determined to be 200 and 50 mg/kg for male and female rats, respectively.

KEYWORDS: Echinophora Platyloba; Rat; Acute Toxicity; Subchronic Toxicity.

INTRODUCTION

The Apiaceae family is of particular interest in food and medicinal chemistry because it includes many commonly consumed plants, such as celery, carrot, fennel, caraway, and dill. Coumarins, polyacetylenes, flavonoids, sesquiterpenes, and phthalides are among the important chemical constituents of this family, along with biologically active essential oils (1-5). Iran’s climate conditions are especially suitable for the growth of apiaceous plants, as demonstrated by the growth of 114 wild genera with 12 endemic genera (6), most of which are consumed daily as food or used in traditional medicine.

Echinophora is a ten-species genus of Apiaceae that contains four species native to Iran, including E. orientalis, E. sibthorpiana, E. cinerea, and E. platyloba (6). Called “Khousharizeh” or “Tigh Touragh” in Persian, E. platyloba is widely used in western and central Iran as a food seasoning and edible vegetable. Local people add the plant to pickles and tomato pastes as an antifungal and antimicrobial preservative (7). These effects have been demonstrated in several experiments. For example, alcoholic extracts of E. platyloba inhibited Candida albicans (7), Trichophyton spp., Microsporum (8), Pseudomonas, and Staphylococcus growth, but it was not effective against Aspergillus (9). Moreover, it could increase the effect of amphotericin B against C. albicans (10). E. platyloba is also traditionally used as an antispasmodic in dysmenorrhea, and its efficacy was proven in a clinical trial (11). Moreover, its...
hydroalcoholic extract and essential oil were shown to have acceptable antispasmodic effects in the rat ileum (12).

Despite the widespread folk uses and pharmacological effects of *E. platyloba*, there have been no toxicological studies on its safety. Therefore, in this study, we investigated the acute and repeated-dose (45 days) toxicity of *E. platyloba* in Wistar rats.

**MATERIALS AND METHODS**

**Plant material and hydroalcoholic extract preparation**

The aerial parts of the plant were collected from Charmahal-Bakhtiary, Iran, in April 2009 and dried away from direct sunlight. The plant was authenticated by M. K., and a voucher specimen (Registration Number 1030) was deposited in the Herbarium of the School of Pharmacy (Shaheed Beheshti University of Medical Sciences, Tehran, Iran). The plant samples were ground to fine powder and macerated with EtOH:H$_2$O (80:20) three times. The extract was concentrated to dryness first via eliminating EtOH in a rotary evaporator and then removing the H$_2$O by freeze drying.

**Evaluation of toxicity following a single-dose administration**

Four-week-old Wistar rats of both sexes were purchased from Razi Research Institute (Hesarak, Karaj, Iran) and acclimated to holding facilities for two weeks prior to dosing. The animals were randomly assigned to control and four treatment groups (five rats per sex per group) and housed in clear plastic cages containing wood shavings for bedding. Each cage contained five rats of the same sex fed normal laboratory chow (Pars Co., Tehran, Iran) and tap water *ad libitum* throughout the study. Environmental conditions were maintained at 23±2 °C and a relative humidity of 40±10% with a 12 h light/dark cycle. At the onset of dosing, the males weighed 164±19 g, and the females weighed 142±15 g. The research was conducted in accordance with internationally accepted principles for laboratory animal use and care (NIH Publication no. 85–23, revised in 1985).

**Administration**

The animals were fasted for 4 h prior to dosing. The extract was administered by gavage at doses of 50, 500, 1,000, and 2,000 mg/kg body weight. The control rats received tap water by gavage in the same volume.

**Observations**

The rats were observed for clinical signs prior to dosing, at 1, 2, 3, 4, 5, 6, 7, and 8 h post-dosing and daily thereafter for 14 days. They were also monitored daily for mortality, any changes in food and water consumption, and any additional clinical or behavioral signs of toxicity. The animal body weights were measured prior to dosing and on days 7 and 14. The numbers of dead animals in each group at the end of the study were expressed as a

![Figure 1 - Changes in male (A) and female (B) rats body weight with duration of acute treatment. Each point represents mean ± SEM, n = 5.](image-url)
percentage, and when possible, the LD₉₀ value was established using the Probit method (13). All of the animals were sacrificed on day 15.

Evaluation of toxicity following subchronic treatment

Group assignment and treatment

The animals were randomly caged in clear plastic cages containing wood shavings for bedding. Dosing was initiated when the rats were 8 weeks old, at which point the males and females weighed 200±19 g and 161±10 g, respectively. The animals were divided into four dose groups (five rats per sex per group). The first group was given 1 ml normal saline and used as a control. The second, third, and fourth groups were given single doses of 50, 200, and 500 mg/kg of E. platyloba by gavage daily. All of the solutions were prepared just prior to dosing and were kept chilled and tightly capped.

In vivo observations

Observations of mortality and toxicological signs were made daily for 45 days. The onset, intensity, and duration of these symptoms, if any, were recorded. The weight of each rat was recorded on day 0 and at weekly intervals throughout the course of the study. Food and water consumption was measured three times per week.

Biochemical and hematology analysis

After 45 days, 12 h-fasted animals were anesthetized with the IP injection of a mixture containing ketamine (40 mg/kg) and xylazine (10 mg/kg). The jugular vein was exposed, and blood samples were obtained by jugular vein puncture (14). The following hematological parameters were determined with the Sysmex K-1000 fully automated hematology analyzer: erythrocyte (RBC), total and differential leukocyte (WBC), hematocrit (Hct), hemoglobin (Hb), platelet count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), platelet distribution width (PDW), and red distribution width (RDW). Blood samples for biochemical analyses were centrifuged at 3,000×g for 5 min, and the plasma was collected and analyzed for glucose, uric acid, creatinine, albumin, cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low-density lipoprotein (VLDL), triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, total protein, and lactate dehydrogenase (LDH) using a COBAS Mira S chemistry analyzer (Roche Diagnostic Systems, West Sussex, England).

Necropsy

Following blood collection, the rats were sacrificed by decapitation, and the organs identified in Table 3 were removed, weighed, and examined macroscopically. The
Table 1 - Hematologic parameters in Wistar rats after 45 days treatment with *E. platyloba*.

| Sex  | Group | WBC (µl) | RBC (10^6/mm³) | Hb (g%) | HCT (%) |
|------|-------|----------|---------------|--------|--------|
| Male | Control | 11200 ± 521 | 9.22 ± 0.1 | 16.4 ± 0.24 | 48.17 ± 0.46 |
|      | 50     | 9900 ± 1121.45 | 8.21 ± 0.3 | 16.01 ± 0.1 | 46.2 ± 0.45 |
|      | 200    | 9300.23 ± 645.23 | 8.28 ± 0.5 | 14.6 ± 0.09 | 44.4 ± 0.42 |
|      | 500    | 8700.65 ± 1117.89 | 7.66 ± 0.9 | 15.8 ± 0.6 | 44.7 ± 0.8 |
| Female | Control | 7700.89 ± 189.49 | 7.46 ± 0.1 | 14.77 ± 0.1 | 39.1 ± 0.6 |
|       | 50     | 8700 ± 425.25 | 7.1 ± 0.07 | 14.36 ± 0.02 | 37.46 ± 0.2 |
|       | 200    | 7300 ± 202.45 | 7 ± 0.2 | 13.6 ± 0.1 | 36.45 ± 0.4 |
|       | 500    | 7700 ± 1128.06 | 7.5 ± 0.1 | 13.3 ± 0.07 | 36.4 ± 1.1 |

| Sex  | Group | MCV (fl) | MCH (pg) | MCHC (%) | MPV (fl) |
|------|-------|----------|----------|----------|----------|
| Male | Control | 53 ± 0.06 | 18 ± 0 | 34.3 ± 0.25 | 7.2 ± 0.25 |
|      | 50     | 52.6 ± 0.3 | 18 ± 0 | 35.25 ± 0.25 | 7.4 ± 0.23 |
|      | 200    | 58.62 ± 0.4 | 18 ± 0.05 | 34.75 ± 0.25 | 6.7 ± 0.18 |
|      | 500    | 50.66 ± 0.06 | 21.3 ± 2.5 | 35.75 ± 0.9 | 9.3 ± 0.89 |
| Female | Control | 52.75 ± 0.06 | 20.3 ± 0.25 | 38.3 ± 0.25 | 6.7 ± 0.1 |
|       | 50     | 52.25 ± 0.45 | 20 ± 2.3 | 37.75 ± 0.05 | 6.66 ± 0.05 |
|       | 200    | 52 ± 0.8 | 21.41 ± 3.6 | 37 ± 0 | 6.65 ± 0.1 |
|       | 500    | 51.75 ± 0.9 | 18.1 ± 2.37 | 36.5 ± 1.1 | 6.5 ± 0.1 |

| Sex  | Group | Platelets (1000/µl) | RDW (%) | PDW (%) |
|------|-------|---------------------|---------|---------|
| Male | Control | 819.58 ± 142 | 13.3 ± 0.2 | 8.65 ± 1 |
|      | 50     | 841.98 ± 56.32 | 13.1 ± 0.08 | 8.4 ± 0.1 |
|      | 200    | 875.6 ± 69.22 | 13.1 ± 0.34 | 7.63 ± 0.2 |
|      | 500    | 800.36 ± 98.3 | 13.05 ± 0.3 | 7.6 ± 0.2 |
| Female | Control | 935 ± 52 | 12.25 ± 0.21 | 7.62 ± 0.1 |
|       | 50     | 854.23 ± 25.4 | 12.1 ± 0.3 | 7.52 ± 0.2 |
|       | 200    | 921.89 ± 89.6 | 12.0 ± 0.31 | 7.46 ± 0.05 |
|       | 500    | 732.6 ± 124.3 | 11.9 ± 0.1 | 7.17 ± 0.2 |

DISCUSSION

Complementary and alternative medicines (CAMs), such as herbal remedies, require thorough safety and efficacy
evaluation due to their growing use all over the world (15). Although many traditional herbal remedies are available and some have been verified by clinical trials, their safety is often still questioned by consumers.

*E. platyloba* DC is native to Iran and is used in traditional medicine and consumed as a vegetable (7,16).

Despite preliminary evidence of its therapeutic benefits, no toxicity studies have been performed on *E. platyloba* extracts. In the present study, the acute and subchronic toxicity of *E. platyloba* DC was evaluated in Wistar rats. The oral LD50 value in this study suggests that *E. platyloba* is a relatively nontoxic plant (17).

The acute treatment with *E. platyloba* extract did not produce any statistically significant difference in hematological parameters. The observed elevation in LDH, an initial indicator of myopathy, in females indicates the potential for muscular damage. LDH levels can be diagnostic of myocardial or skeletal muscle injuries (14), but there were no treatment-related heart histopathological findings. Thus, the potential effects of *E. platyloba* treatment on cardiac muscle should be investigated further.

A significant increase in relative lung weight was also observed. This phenotype may have been caused by the congestion of the alveolar capillaries by retaining blood in the lung. Moreover, the intra-alveolar hemorrhage observed in the male rats (500 mg/kg) indicates that *E. platyloba* may have been retained in the lung and therefore was not considered to be a treatment-related effect.

### Table 2 - Biochemical parameters of Wistar rats after 45 days treatment with *E. platyloba*.

| Sex  | Dose mg/kg | blood sugar (mg/dl) | Creatinine (mg/dl) | Uric Acid (mg/dl) | Triglycerides (mg/dl) |
|------|------------|---------------------|--------------------|------------------|---------------------|
| Male | Control    | 162 ± 10.19         | 0.42 ± 0.02        | 2.96 ± 0.9       | 55.2 ± 7.13         |
|      | 50         | 202.6 ± 23.02       | 0.42 ± 0.04        | 2.5 ± 0.54       | 48 ± 7.34           |
|      | 200        | 219.65 ± 23.75      | 0.54 ± 0.05        | 3.92 ± 0.73      | 68.8 ± 6.7          |
|      | 500        | 379.5 ± 4-05        | 0.57 ± 0.09        | 2.97 ± 0.35      | 72.8 ± 17.6         |
| Female | Control   | 291.3 ± 28.34        | 0.35 ± 0.08        | 5 ± 0.65         | 82.2 ± 15.5         |
|      | 50         | 151.4 ± 11.9*       | 0.44 ± 0.05        | 4.14 ± 0.84      | 66.6 ± 11.25        |
|      | 200        | 148.2 ± 2.7*        | 0.5 ± 0.00         | 3.78 ± 0.051     | 52 ± 8.24           |
|      | 500        | 177.6 ± 23.64       | 0.46 ± 0.06        | 3.08 ± 0.99      | 62 ± 6.1            |

| Sex  | Dose mg/kg | Cholesterol (mg/dl) | HDL (mg/dl) | LDL (mg/dl) | VLDL (mg/dl) |
|------|------------|---------------------|-------------|-------------|--------------|
| Male | Control    | 72 ± 7.17           | 38.4 ± 4.67 | 22.4 ± 3.3  | 11.2 ± 1.3   |
|      | 50         | 84.2 ± 4.93         | 48.4 ± 7.6  | 26.2 ± 6.5  | 9.6 ± 7.4    |
|      | 200        | 76.4 ± 4.26         | 34.6 ± 4.2  | 27.4 ± 5.7  | 14.4 ± 1.63  |
|      | 500        | 92.25 ± 4.75        | 43 ± 6.67   | 36.25 ± 7.6 | 13 ± 0.7     |
| Female | Control   | 112.4 ± 9.6         | 69.5 ± 6.7  | 21.5 ± 3.8  | 16.6 ± 1.69  |
|      | 50         | 91 ± 3.83           | 91 ± 3.8    | 34.6 ± 5.6  | 13.2 ± 2.1   |
|      | 200        | 88.6 ± 6.67         | 89.2 ± 6.4  | 28 ± 7.7   | 10.4 ± 1.72  |
|      | 500        | 98.2 ± 7.37         | 92 ± 5.16   | 33.8 ± 6.2  | 12.4 ± 1.28  |

| Sex  | Dose mg/kg | Urea (g %) | SGOT (IU/L) | SGPT (IU/L) | LDH (IU/L) |
|------|------------|------------|-------------|-------------|------------|
| Male | Control    | 41.6 ± 1.91| 130.8 ± 16.25 | 48 ± 4.84 | 942± 138.7  |
|      | 50         | 45 ± 4.48  | 144 ± 19.45  | 58 ± 6.39  | 1293 ± 189.13 |
|      | 200        | 50 ± 3.59  | 170.4 ± 16.7 | 61.25 ± 10.2 | 2036.6 ± 117.98* |
|      | 500        | 52.5 ± 1.65| 191 ± 15.02  | 71.25 ± 7.2 | 2043 ± 122.88* |
| Female | Control   | 60 ± 6.15  | 184.2 ± 26.02 | 66.8 ± 9.84 | 2126 ± 137.12 |
|      | 50         | 57.8 ± 6.03 | 206.2 ± 20.63 | 71 ± 9.18 | 1992.4 ± 243.18 |
|      | 200        | 46.6 ± 3.57 | 122.8 ± 5.21 | 41 ± 1.5 | 1743.3 ± 37.6  |
|      | 500        | 56.4 ± 4.83 | 126.8 ± 14.51 | 52.4 ± 2 | 1555.25 ± 86.96 |

| Sex  | Dose mg/kg | Albumin (gr/dl) | Total Protein (mg/dl) |
|------|------------|-----------------|-----------------------|
| Male | Control    | 3.98 ± 0.15    | 9.12 ± 0.56           |
|      | 50         | 3.59 ± 0.1     | 8.97 ± 0.39           |
|      | 200        | 3.25 ± 0.16    | 8.56 ± 0.48           |
|      | 500        | 3.73 ± 0.19    | 8.75 ± 0.72           |
| Female | Control   | 3.32 ± 0.26    | 7.86 ± 0.6            |
|      | 50         | 2.94 ± 0.17    | 7.69 ± 0.52           |
|      | 200        | 3.13 ± 0.33    | 8.14 ± 0.69           |
|      | 500        | 3.76 ± 0.18    | 7.39 ± 0.49           |

Data presented as mean ± S.E.M. for N = 5. Significantly different from control: *p < 0.05.
considered to be 200 and 50 mg/kg/day for male and female rats, respectively. This result indicates that gender is one factor that could influence the response to *E. platyloba*, and females are more sensitive than males to its subchronic toxicity.

**ACKNOWLEDGMENTS**

This study was financially supported by the Research Council of Tehran University of Medical Sciences, Iran.

**AUTHOR CONTRIBUTIONS**

Mirghazanfari SM designed and organized the study. Hosseinzadeh L interpreted the results, performed data analysis, and revised the manuscript. Adani M was responsible for animal experiments and data collection. Kamali-Nejad M was responsible for plant identification and data collection.

**REFERENCES**

1. Christensen L, Brandt K. Bioactive polyacetylenes in food plants of the Apiaceae family: occurrence, bioactivity and analysis. J Pharm Biomed Anal. 2006;41(3):683-93. http://dx.doi.org/10.1016/j.jpba.2006.01.057.
2. Iranshahy M, Iranshahi M. Traditional uses; phytochemistry and pharmacology of asafoetida (*Ferula assa-foetida* oleo-gum-resin)-A review. J Ethnopharmacol. 2011;134(1):1-10, http://dx.doi.org/10.1016/j.jep.2010.11.067.
3. Nazari ZE, Iranshahi M. Biologically active sesquiterpene coumarins from *Ferula* species. Phytother Res. 2011;25(3):315-23.
4. Sajjadi SE, Zeinvand H, Shokoohinia Y. Isolation and identification of osthole from the fruits and essential oil composition of the leaves of *Prangos asperula* Boiss. Res Pharm Sci (RPS). 2009;4(1):19-23.
5. Shokoohinia Y, Sajjadi SE, MehrAmiri P. Isolation of 3-butyldien-4,5-dihydrophthalalide and steroids from *Kelussia odonatisima*, a Persian food seasoning. Planta Med. 2010;76:328.
6. Mozaffarian V. A Dictionary of Iranian Plant Names. Tehran: Farhang Mosoer Publications; 1996.
7. Avizhgan M, Hafizi M, Saadat M. Anti-fungal effect of hydroalcoholic extract of *Echinophora platyloba* against *Candida albicans*. Iranian Journal of Medicinal and Aromatic Plants Winter. 2006;21(4330):545-52.
8. Avizhgan M, Saadat M, Nilloofarshad MR, Hafizi M. Anti fungal effect of *Echinophora platyloba* extract on some common dermatophytes. J Med Plants. 2006;3(18):10-6.
9. Entezari M, Hashemi M, Ashki M, Ebrahimian S, Bayat M, Saraji AR, et al. Studying the effect *Echinophora platyloba* extract on bacteria (*Staphilococcus aureus* and *Pseudomonas aeruginosa*) and fungi (*Candida albicans, Aspergillus flavus* and *Aspergillus niger*) in vitro. World J Med Sci. 2009;4(2):89-92.
10. Mahboubi M, Avijan M, Darabi M, Kiasiyan N. Anticandidial activity of *Echinophora platyloba* against *Candida albicans* and comparison with amphotericin. J Med Plants. 2009;8(30):36-43.
11. Delaram M, Sadeghiyan Z. The effect of *Echinophora platyloba* extract on primary dysmenorrhea. Arak Med Univer J. 2010;13(3):61-7.
12. Sadraei H, Asghari G, Yahyobef K. Study of the effect of hydro-alcoholic and essential oil of *Echinophora platyloba* on rat isolated ilium contractions in vitro. J Res Med Sci (JPRS). 2003;5(Supplement 2):150-5.
13. de Angelis Pereira MC, Carvalho JCT, Lima LM, Caputo LRG, Ferreira LR, Fiorini JE, et al. Toxicity of a subchronic treatment with hydroalcoholic crude extract from *Solanum granatum* (Ruiz et Pav) in rats. J Ethnopharmacol. 2003;89(1):97-9, http://dx.doi.org/10.1016/S0378-7849(03)00266-6.
14. Rasekh HR, Nazari P, Kamili-Nejad M, Hosseinzadeh L. Acute and subchronic oral toxicity of Galago officinalis in rats. J Ethnopharmacol. 2008;116(1):21-6, http://dx.doi.org/10.1016/j.jep.2007.10.030.
15. Firenzuoli F, Gori L. Herbal medicine today: clinical and research issues. Evid-Based Compl Alt Med. 2007;4(11):37-40, http://dx.doi.org/10.1093/ecam/nem096.
16. Avijan M, Mahboubi M, Darabi M, Saadat M, Sarikhanii S, Kassiyan N. Overview on *Echinophora platyloba*, a synergetic antifungal agent candidate. J Yeast Fungal Res. 2010;22(1):88-94.
17. Lu FC, Kacew S. Lu’s Basic Toxicology: Fundamentals, target organs and risk assessment. 5 ed. New York: Informa Healthcare 2009.
18. Raza M, Al-Shabanah OA, Al-Hadiyah YM, Al-Majed AA. Effect of prolonged vagalobatin treatment on haematological and biochemical parameters in plasma, liver and kidney of Swiss albino mice. Sci Pharm. 2002;70(2):135-45.

**Table 3 - Relative organ weight at termination of treatment with *E. platyloba* (g % body weight).**

| Sex | Dose mg/kg | liver% | kidney% | Heart% | Lung% |
|-----|------------|--------|---------|--------|-------|
| Male | Control | 2.9 ± 0.136 | 0.76 ± 0.024 | 0.4 ± 0.072 | 0.56 ± 0.024 |
| 50  | 3.03 ± 0.21 | 0.79 ± 0.004 | 0.378 ± 0.015 | 0.66 ± 0.04 |
| 200 | 2.86 ± 0.15 | 0.79 ± 0.066 | 0.34 ± 0.024 | 0.71 ± 0.08 |
| Female | Control | 4.1 ± 0.2 | 0.79 ± 0.1 | 0.39 ± 0.055 | 0.54 ± 0.03 |
| 50  | 3.1 ± 0.25 | 0.822 ± 0.052 | 0.41 ± 0.006 | 0.67 ± 0.03 |
| 200 | 3.03 ± 0.14 | 0.831 ± 0.0052 | 0.37 ± 0.031 | 0.63 ± 0.056 |
| 500 | 3.26 ± 0.28 | 0.88 ± 0.04 | 0.4 ± 0.032 | 0.80 ± 0.07* |

Data presented as mean ± S.E.M. for n = 5. Significantly different from control: *p < 0.05.